Skip to main content

Market Overview

DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share

Share:
DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share
  • Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX) for $37 per share in an all-cash transaction, corresponding to a total equity value of approximately $1.8 billion.
  • The offer price represents around 23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February (the date before press rumors regarding a potential sale of the company).
  • Luminex makes COVID-19 laboratory tests along with a suite of other biological testing technologies.
  • In March, it applied to the FDA for emergency approval of a lab test that combines tests for COVID-19 and the flu.
  • The acquisition will broaden DiaSorin’s positioning in the molecular diagnostics space gaining access to Luminex’s molecular diagnostics multiplexing technology and a more significant foothold in the U.S. market.
  • Following the acquisition, the new entity will have a combined 2020 revenue of approximately €1.25 billion, adjusted EBITDA of roughly €472 million, and a favorable net financial position of about €335 million.
  • The transaction will be funded through a mix of cash and external financing. It’s expected to close in the third quarter.
  • DiaSorin also signed a $1.1 billion term loan due in 2026 and a $500 million bridge loan due within 12 months with a group of banks including BNP, Citi, Mediobanca, and UniCredit.
  • Price Action: LMNX shares gained 10.8% at $36.5, whiles DSRLF shares are up 0.49% at $165.81 in premarket trading on the last check Monday.
 

Related Articles (LMNX + DSRLF)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19Biotech M&A News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com